United States of America to provide data on Alzheimer's vaccine at conference AD ​​/ PD 2019



[ad_1]

DUBLIN and DALLAS, March 28, 2019 / PRNewswire / – United Neuroscience (UNS), a clinical level biological company that is promoting a new class of drugs to ban and ban the brain chaos, today it has toured a production of t His findings for Phase IIa in his clinical research output, UB-311, at the 14th International Conference on Alzheimer's Galaxies and Parkinson's Diseases (AD / PD) t Lisbon, Portugal, from March 26-31, 2019.

"UNS works to resolve some of the most challenging challenges in the world, including those associated with Alzheimer's," he said. T Mei Mei Hu, UNS Chief Executive. "As pioneers of developing endobody vaccines, we remain committed to changing the lives of patients and families affected by neurodegenerative diseases."

Display information:

Immunotherapy Active with UB-311 vaccine: Level IIA results, double blind, blind blind, controlled by Placebo, parallel with 3 arms, Multicenter Study t

Presenter: Jean-Cosme Dodart, Ph.D.
Date: Friday, March 29, 2019, 9:45 – 10:00 am. GMT
Place: Centro of Congressos de Lisboa, Full Hall – Audium I
Session Title: Symposium 32: Abeta Immunotherapies and ban BACE1

About UB-311 in Alzheimer's disease
The active vaccination of people against Ai has continued to be safely and effectively performed. Other vaccination efforts have shown that fewer antibody drugs and response rates or important safety issues such as encephalitis had a T-cell device. UB-311 is an UBITh ™ active vaccine aimed at N-terminus of peptides Aβ and is designed to avoid the circumcision of B-cell cells and avoiding inflammation of the cell t -T. In the Phase I study, UB-311 immunization enhanced anti-Aβ antibodies in all patients with a recommendation for intellectual stability.

About Neuroscience United
The United Nuroscience (UNS) is a clinical level biotechnology company dedicated to the development of active active vaccination for the brain. A global company with main offices Dublin, Irelandwith work in t Taiwan and StatesHowever, UNS was set up to tackle the social and economic responsibility of Alzheimer's diseases and other neurodegenerative diseases and aims to quickly bring applicants forward and through clinical trials with the aim of delivering t advanced treatment for patients. For more information visit www.unitedneuroscience.com.

Follow UNS on Twitter https://twitter.com/UNSTechBio and on LinkedIn at https://www.linkedin.com/company/unitedneuroscience.

Contact the media
David Schull no Brittanie Dougherty
Russo Partners, LLC
(212) 845-4271
(646) 942-5634
[email protected]artnersllc.com
[email protected]

View original content: http: //www.prnewswire.com/news-releases/united-neuroscience-to-present-data-on-alzheimers-vaccine-at-the-2019-adpd-conference-300819992.html

SOURCE United Neuroscience

[ad_2]
Source link